جستجوی استاد راهنمای دانشگاهی

• Environmental Health Engineering
• Wastewater-Based Epidemiology
• Bioremediation
• +۷ مورد دیگر

Rolf Halden is a Professor and Center Director at Arizona State University, holding appointments in the School of Sustainable Engineering and the Built Environment, the Biodesign Center for Environmental Health Engineering, and the Global Futures Scientists and Scholars program. He is a leading expert in environmental health engineering, wastewater-based epidemiology, and bioremediation. Education: Ph.D. in Civil (Environmental) Engineering, University of Minnesota (1997) M.S. in Civil (Environmental) Engineering, University of Minnesota (1994) M.S. in Biology, Technical University of Braunschweig, Germany (1992) Postdoctoral Fellow, Environmental Science, Lawrence Livermore National Laboratory (1998) Research Focus: Halden’s research integrates environmental chemistry, public health, and sustainability to understand how anthropogenic chemicals affect ecological and human health. His lab uses advanced mass spectrometry (LC-MS/MS, MALDI-TOF) to track pollutants such as PPCPs, microplastics, pesticides, and dioxins across air, water, soil, and biological systems. He pioneered the use of wastewater treatment plants as public health observatories, enabling real-time tracking of disease, drug use, and environmental exposures. Scientific Awards & Recognition: Leadership Award, Arizona State University (2018) Rocky Mountain Emmy Award (2018) Leroy E. Burney Lecturer, Johns Hopkins School of Public Health (2011) ACS Expert Program Member (2014–present) NIEHS Superfund R01 Working Group National Leader (2012–2014) Labs & Teams: Halden is the Founding Director of the Biodesign Center for Environmental Health Engineering at ASU, where he leads a multidisciplinary team focused on environmental proteomics, bioremediation, and diagnostic tool development. He also co-leads the Human Health Observatory , a national wastewater monitoring network. Grants & Funding: Halden has secured major funding from NSF, NIH, EPA, DoD, and private industry. Notable projects include the development of in-situ groundwater monitoring devices, national wastewater surveillance of SARS-CoV-2, and studies on microplastics and neurodegenerative disease.

Vivek Shenoyمشاهده پروفایل

استاد

• Mechanobiology
• Multiscale Modeling
• Biomaterials
• +۶ مورد دیگر

Vivek Shenoy is the Eduardo D. Glandt President's Distinguished Professor at the University of Pennsylvania, with primary appointments in the Department of Materials Science and Engineering and secondary appointments in Bioengineering and Mechanical Engineering and Applied Mechanics. He leads the Multiscale Mechanobiology and Biomaterials Laboratory, which focuses on developing theoretical frameworks and numerical methods to understand complex biological and engineering systems across multiple length scales. Shenoy's research spans mechanobiology, chromatin organization, cell mechanics, and biomaterials. His work addresses the fundamental challenge of modeling how small-scale cellular phenomena couple with long-range tissue-level interactions across micrometers to centimeters. By integrating insights from soft matter physics, solid mechanics, chemistry, and applied mathematics, his group develops multiphysics continuum and mesoscale theories to elucidate mechanisms controlling both biological and engineering systems. His recent publications demonstrate an increasing focus on nuclear mechanics, chromatin organization, and the interplay between mechanical forces and gene regulation. Analysis of Shenoy's publication record reveals a strong interdisciplinary approach, with high-impact papers spanning biophysics, materials science, and cell biology. His work shows consistent evolution from fundamental mechanics of materials to complex biological systems, with recent emphasis on the mechanical regulation of chromatin architecture, cell migration dynamics in 3D environments, and mechanotransduction in development and disease. His publications appear regularly in top journals including Nature, Science, and their affiliated publications, demonstrating significant influence across multiple fields. Eduardo D. Glandt President's Distinguished Professor Multiple publications in Nature, Science, and PNAS Active research program with publications through 2025 Shenoy actively mentors students and postdocs through his laboratory, with numerous co-authored publications indicating strong mentorship. His research program appears to be well-funded through multiple grants supporting his work in mechanobiology and biomaterials. The Multiscale Mechanobiology and Biomaterials Laboratory maintains active collaborations across disciplines and institutions, reflecting the interdisciplinary nature of his research. The Multiscale Mechanobiology and Biomaterials Laboratory, housed within the Department of Materials Science and Engineering at the University of Pennsylvania, serves as the primary research hub for Shenoy's work. The lab maintains an active presence on social media (Twitter: @ShenoyLab) for updates on activities and publications. Their research approach combines theoretical modeling with experimental validation to address fundamental questions at the interface of mechanics, materials science, and biology.

• Pulmonary vasculature
• Heart Failure
• Cardiopulmonary Immunology

Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.

Paul Stuppleمشاهده پروفایل

استاد

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +۳ مورد دیگر

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

Jenny Ouyangمشاهده پروفایل

دانشیار

• Endocrinology
• Urban Ecology
• Physiological Adaptation
• +۴ مورد دیگر

Jenny Ouyang is an Associate Professor in the Department of Biology at the University of Nevada, Reno , where she also serves as Director of the Ecology, Evolution and Conservation Biology graduate program. She earned her B.S. and B.A. from the University of California, Irvine (2007), followed by M.A. and Ph.D. in Ecology and Evolutionary Biology from Princeton University (2009, 2012). Her research focuses on the ecology and evolution of physiological systems , particularly how hormonally regulated traits enable organismal adaptation to environmental changes like urbanization , light pollution , and endocrine stress responses . Education: Ph.D., Ecology and Evolutionary Biology, Princeton University (2012) M.A., Ecology and Evolutionary Biology, Princeton University (2009) B.S., Biology, University of California, Irvine (2007) B.A., French, University of California, Irvine (2007) Her work integrates neuroendocrine mechanisms with ecological contexts to understand phenotypic flexibility and epigenetic adaptation in birds. Recent projects examine how artificial light at night disrupts circadian rhythms, hormonal profiles, and parental behaviors across urban-rural gradients. She has secured major grants including the NSF CAREER award (2022) for studying urbanization and NIH COBRE funding (2017) as part of a neuroscience team. Key collaborations include Dr. Maria Echeverry at Universidad Pontificia Javeriana in Colombia through her 2023 Fulbright award . The Ouyang Lab combines natural and laboratory experiments to investigate stress physiology, with recent papers analyzing glucocorticoid responses to urbanization, gene expression patterns under light pollution, and epigenetic reorganization in response to environmental stressors. Her publications span top journals like Proceedings of the Royal Society B , Biology Letters , and Ecology Applications , where her 2022 paper on lead pollution and reproduction was highlighted by ESA and Swedish Radio. Scientific Awards & Recognition: US Fulbright Scholars Award (2023) NSF CAREER grant (2022) NIH COBRE grant (2017) as team member Advising students like Valentina Alaasam (NSF GRFP awardee) and Ivan Celso Carvalho Provinciato (Dean's Merit Fellowship)

Weiping Tangمشاهده پروفایل

استاد

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +۵ مورد دیگر

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

Britt Adamsonمشاهده پروفایل

دانشیار

• Stress Response Networks
• DNA Damage Response
• Genome Editing
• +۳ مورد دیگر

Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.

• Immunology
• Genomics
• Multiomics Analysis
• +۳ مورد دیگر

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.

Jane Gairمشاهده پروفایل

استاد آموزشی

• Medical Education
• Medical Genetics
• Science Outreach
• +۱ مورد دیگر

Dr. Jane Gair is a tenured Teaching Professor in the Division of Medical Sciences at the University of Victoria, where she teaches first and second-year medical students in the Island Medical Program (IMP). She serves as IMP Site Lead for Case-Based Learning (CBL) and Director for CBL Faculty Development, leading provincial curriculum implementation and faculty training. Her academic credentials include: BSc from McMaster University BSc from University of British Columbia (UBC) PhD from University of British Columbia (UBC) Her research centers on medical education methodologies including Problem-Based Learning (PBL) and Case-Based Learning (CBL), with emphasis on small-group pedagogy effectiveness. She maintains active scholarship in medical genetics and personalized medicine, as demonstrated through public lectures on epigenetics and genetic testing. International collaborations extend her work to the University of Newcastle (Australia), Patan Academy of Health Sciences (Nepal), and National University of Defense Technology (China). Dr. Gair directs UVic's branch of the national Let's Talk Science Outreach Program, engaging medical students in K-12 STEM education across Vancouver Island. This initiative serves as a core component of the FLEX course curriculum where she mentors students as Advisor, Assessor, and Supervisor. Her provincial faculty development work indicates ongoing grant-supported activities though specific funding sources aren't detailed. She maintains affiliations with the Centre for Biomedical Research (CBR) at UVic and the Centre for Health Education Scholarship (CHES) at UBC. Her leadership in Let's Talk Science coordinates medical student volunteers and community partners in delivering science literacy programs, with recent activities including 2023-2024 Mini Med School sessions on AI in healthcare, diabetes management, and genetic testing.

Weiqiang Chenمشاهده پروفایل

استاد

• Lab-on-a-Chip
• Organ-on-Chip
• Biomaterials
• +۷ مورد دیگر

Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.

• Microbiology
• Infectious Diseases
• Cell Biology
• +۷ مورد دیگر

Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.

Jennifer A. Smithمشاهده پروفایل

دانشیار

• Genetic Epidemiology
• Epigenomics
• Aging
• +۴ مورد دیگر

Jennifer A. Smith, PhD, MPH is an Associate Professor of Epidemiology and Research Associate Professor of Survey Research at the University of Michigan School of Public Health . She also serves as Director of the Certificate in Public Health Genetics and is Assistant Director of the Cohort Development working group for U-M Precision Health and the Michigan Genomics Initiative. Education: PhD, Epidemiology, University of Michigan (2011) MA, Statistics, University of Michigan (2009) MPH, Health Management and Policy, University of Michigan (2005) BS, Biological Sciences, Cornell University (2001) Research Interests: Dr. Smith is a genetic epidemiologist whose work lies at the intersection of genomics, epigenomics, and social epidemiology . She investigates how genetic, epigenetic, and transcriptomic variation influence age-related chronic diseases such as cardiovascular disease, hypertension, dementia, and cognitive decline. A major focus is understanding how social, psychosocial, and neighborhood determinants interact with genetic risk to shape socioeconomic and racial/ethnic health disparities . Research Projects: Her work leverages large, multi-ethnic cohorts including the Health and Retirement Study (HRS), GENOA, SWAN, MESA, and LASI. She is a core faculty member of the Center for Social Epidemiology and Population Health (CSEPH) , and affiliated with MiCDA, the Center for Midlife Science, and the PNG Program . She also collaborates with leading consortia such as CHARGE and TOPMed. Selected Trends in Publications: Her recent work (2022–2025) emphasizes epigenetic mediation of social determinants on cardiovascular and cognitive health, polygenic risk scores across diverse ancestries , and multi-omics integration in aging and disease. These studies consistently highlight how social environments and genetic architecture jointly influence health outcomes across populations. Contact: Email: smjenn@umich.edu Office: 734-615-9455 Address: 2631 SPH I, 1415 Washington Heights, Ann Arbor, MI 48109

Margaret Bublitzمشاهده پروفایل

دانشیار

• Perinatal Mental Health
• Integrated Behavioral Health
• Mindfulness-Based Interventions
• +۶ مورد دیگر

Margaret Bublitz is Associate Professor at Brown University with joint appointments in the Department of Psychiatry and Human Behavior , Department of Medicine , and Department of Obstetrics and Gynecology . She holds secondary appointments at the School of Public Health as Senior Investigator and Behavioral and Social Sciences faculty member. Dr. Bublitz earned her PhD in Clinical Psychology (2010) from the University of British Columbia, followed by postdoctoral training in Cardiovascular Behavioral Medicine at Brown Medical School. Her research focuses on: Psychological stress pathways to adverse perinatal outcomes Maternal childhood maltreatment effects on neurobiology Mindfulness interventions for hypertension and preterm birth prevention Her 15 most recent publications demonstrate expertise in perinatal mental health , sleep-disordered breathing , HPA axis regulation , and fetal neurodevelopment , with significant collaborations in neuroendocrinology and maternal-infant health disparities . Scientific recognition includes: 2024-2025 Global Fulbright Scholarship 2022 Brown Early Career Research Achievement Award Multiple NIH and foundation grants exceeding $6 million Bublitz leads NIH-funded projects examining mechanisms of mindfulness training (R01HL157288) and serves as mentor in the MORPHE Trial for digital maternal health innovations. She is a licensed psychologist and active member of Brown's Stress, Trauma and Resilience (STAR) Institute and Mindfulness Center .

Tracey Gallowayمشاهده پروفایل

دانشیار

• Indigenous health
• circumpolar populations
• nutrition transition
• +۷ مورد دیگر

Tracey Galloway is an Associate Professor in the Department of Anthropology at the University of Toronto Mississauga (UTM), where she conducts critical research on Indigenous health disparities and policy interventions in northern Canada. Her work bridges medical anthropology, public health, and community-based participatory research to address systemic inequities affecting circumpolar populations. Education: PhD, McMaster University, 2008 MA (institution unspecified) BA (institution unspecified) BScN (institution unspecified) Dr. Galloway's research program centers on chronic disease risk assessment and health system improvement in Indigenous communities, with specific expertise in nutrition transition, food security, child growth patterns, and public health policy evaluation. She examines the impact of federal programs like Nutrition North Canada while developing community-led solutions for health equity. Her methodological approach combines quantitative analysis of health outcomes with qualitative community engagement, emphasizing Indigenous research sovereignty and decolonizing methodologies. Her publication record reveals consistent thematic focus across 15 recent articles, demonstrating interdisciplinary collaboration between anthropology, epidemiology, and health economics. Key trends include rigorous evaluation of colonial impacts on Indigenous food systems, innovative analysis of subsidy program effectiveness, and centering Indigenous patient experiences in healthcare design. Her work consistently prioritizes community-defined research questions and actionable policy recommendations. Dr. Galloway actively mentors graduate students including Darci Belmore, Carly Checholik, Neda Maki, and Hiliary Monteith, guiding research on Indigenous health determinants and policy interventions. While specific grant details aren't publicly enumerated, her collaborative projects involve partnerships with Indigenous communities across Northern Canada and interdisciplinary teams addressing complex health system challenges. She maintains strong community partnerships for her applied research, particularly in Nunavut and Northwestern Ontario, working directly with Anishinabeck and Inuit communities to translate findings into culturally safe health initiatives and policy reforms that address the root causes of health inequities.

Ross L. Levineمشاهده پروفایل

استاد

• Hematology
• Oncology
• Genetics
• +۴ مورد دیگر

Ross L. Levine, MD, is a distinguished Professor and Physician-Scientist at Memorial Sloan Kettering Cancer Center (MSKCC), holding the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes (MDS). As Senior Vice President of Memorial Hospital’s Translational Research division, he leads groundbreaking work in hematologic malignancies, particularly leukemia and myeloproliferative neoplasms (MPNs). His research integrates clinical care with genomic and molecular studies to develop targeted therapies. Levine received his MD from Johns Hopkins University School of Medicine, followed by residency in Internal Medicine at Massachusetts General Hospital and fellowship in Hematology/Oncology at Dana-Farber Cancer Institute. Education: MD, Johns Hopkins University School of Medicine Residencies: Internal Medicine, Massachusetts General Hospital Fellowships: Hematology/Medical Oncology, Dana-Farber Cancer Institute Levine’s research focuses on the genetic and epigenetic drivers of myeloid cancers, including JAK-STAT pathway mutations in MPNs and AML. His team explores therapeutic strategies targeting CXCL8/CXCR2 signaling and clonal hematopoiesis. Key contributions include identifying JAK2 mutations in MPNs and advancing single-cell mutation analysis for clonal evolution studies. His clinical expertise includes treating patients with acute myeloid leukemia (AML), polycythemia vera, and myelofibrosis, performing bone marrow biopsies, and leading clinical trials for targeted therapies. Levine has pioneered translational research programs linking lab discoveries to patient care, emphasizing precision medicine. Awards & Honors: Pershing Square Sohn Prize (2014), Howard Hughes Medical Institute Early Career Award (2007), and multiple Leukemia & Lymphoma Society accolades. He holds leadership roles in professional societies, including co-chairing the American Society of Hematology’s 2016 Scientific Program. Levine’s lab, part of the Human Oncology & Pathogenesis Program (HOPP), collaborates with institutions globally. His work has been published in high-impact journals like Cancer Cell , Nature , and Blood , advancing understanding of cancer genetics and therapeutic innovation.